Haemonetics P/E Ratio

Haemonetics (HAE) currently reports a P/E ratio of 50.47. That is above the Healthcare sector average of 25.9. Use the charts on this page to explore Haemonetics's P/E ratio history and peer comparisons.

Haemonetics's P/E ratio of 50.47 is higher than the Healthcare sector average of 25.9. That is roughly 94.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Haemonetics's market price to a fundamental measure such as earnings, sales, or book value. At 50.47, HAE can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of 50.47, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.9. From there, open related valuation or income-statement pages for Haemonetics, and consider following HAE for alerts when major investors trade the stock.

Haemonetics is classified in the Healthcare sector. On P/E ratio, it currently shows 50.47 versus a sector average near 25.9. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HAE with unrelated industries.